INmune Bio, Inc. (NASDAQ:INMB) Receives Average Rating of "Buy" from Brokerages

INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $22.80.

A number of research firms have recently commented on INMB. Scotiabank raised their price objective on shares of INmune Bio from $22.00 to $23.00 and gave the stock a "sector outperform" rating in a report on Tuesday, February 11th. RODMAN&RENSHAW raised INmune Bio to a "strong-buy" rating in a report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on INmune Bio in a research note on Tuesday, January 28th. They set a "buy" rating and a $23.00 price objective for the company. Finally, Maxim Group increased their price objective on shares of INmune Bio from $22.00 to $30.00 and gave the stock a "buy" rating in a report on Thursday, February 13th.

INmune Bio Stock Performance

Shares of NASDAQ:INMB traded down $0.36 during midday trading on Friday, hitting $6.49. The company's stock had a trading volume of 122,981 shares, compared to its average volume of 247,081. INmune Bio has a fifty-two week low of $4.32 and a fifty-two week high of $12.72. The stock has a market capitalization of $148.70 million, a price-to-earnings ratio of -2.96 and a beta of 1.86. The stock's 50 day simple moving average is $8.36 and its 200 day simple moving average is $6.49.

INmune Bio (NASDAQ:INMB - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.14. As a group, analysts anticipate that INmune Bio will post -2.24 EPS for the current year.

Institutional Investors Weigh In On INmune Bio

Several large investors have recently modified their holdings of the business. Wells Fargo & Company MN boosted its stake in INmune Bio by 51.0% in the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company's stock worth $30,000 after purchasing an additional 2,155 shares during the period. Beacon Pointe Advisors LLC acquired a new position in shares of INmune Bio during the fourth quarter worth about $48,000. JPMorgan Chase & Co. boosted its position in shares of INmune Bio by 93.0% during the fourth quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company's stock worth $53,000 after buying an additional 5,461 shares during the period. Two Sigma Advisers LP bought a new position in shares of INmune Bio during the fourth quarter worth about $59,000. Finally, Mariner LLC acquired a new stake in INmune Bio in the 4th quarter valued at approximately $65,000. 12.72% of the stock is currently owned by institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.